EmPower Research
develops Research Papers based on client and market needs.
The Indian CRO Report is one such effort in that direction,
which will be followed by other topics.
Indian Contract Research Organization
Industry Report
India currently
stands as one of the highest ranked emerging countries
in global contract research in the pharmaceuticals industry
followed by Italy and China, and is expected to grow by
20% compounded annual growth, over the next five years.
Over 30 global top-ranking contract research organizations
(CROs), including Quintiles and Kendle have set up centers
in India. Several major pharma companies are also setting
up new centers, expanding their existing centers, or revisiting
their strategies after a long time lapse. Clinical research
is a major driver for the Indian CRO industry.
The report titled
'Indian Contract Research Industry' (CRO-nicles) captures
the industry's current position, trends, challenges and
its outlook by speaking to the top line industry executives
first hand.
The key highlights
of the report include an overview of the Indian clinical
trials market, its size, and costs incurred, advantages
and future outlook. The report examines the clinical trials
market scenario, critical success factors driving the
industry and key issues related to government regulations
and governing clinical trials. In addition, the report
also explores the outsourcing opportunities, industry
dynamics and anticipated changes in the industry.
As part of the report,
profiles of major Indian CRO companies covering aspects
like services offered, key people, clinical phases and
financials for the last two years are also presented.
For further enquiries/queries,
Please e-mail to
cro-nicles@empowerresearch.com or call +1 646 290
8199 between 9:00 am Eastern and 6:00 pm Eastern (please
note this is a US number).
You will need Adobe
Acrobat Reader installed to view this PDF document. To
download it, click
here.
If you already have the reader
installed but are having problems viewing the PDF, please
upgrade to the newest version.
